2022.06. 30 (Taipei) (PharmaEssentia, 6446)

·  In 2021, PharmaEssentia was the first year notably invited by DJSI -S&P Global CSA (Corporate Sustainability Assessment ) to participant in CSA and has earned as top performer above 92 Percentile (100 percentile = highest performer)  on ESG issues in the global biotechnology industry. 

·   In 2021, Sustainlytics was the 1st time to recognize PharmaEssentia continuous improvements on ESG Risks Management , acknowledged the performance by reducing ESG Risk Rating to Medium Risk and ranking as 15th  performer ( 1st = lowest risk ) in the biotechnology subindustry. 

   Highlights of 2021 ESG activities and performance 

 Business ethics , integrity and compliance（8 Performance Highlights）

   Voluntary sustainability reporting: Publishing 2021 Sustainability Report in English and Chinese. Obtained third-party assurance

   Information disclosure in line with Sustainability Accounting Standards Board (SASB): Disclose the evaluation of ESG performances

     in line with international standards to ensure the quality and consistency of disclosed information 

   Invited to participate in S&P CSA for the first time: Total score reached 92nd percentiles among global pharmaceutical companies,     

     successfully propelling PEC onto the global market 

   Reached the Top 6%-20%: On the OTC corporate governance evaluation scale 
   TCSA Gold Medal in CSR Report: Received Gold Medal for CSR Report in medical healthcare sector of the 14th TCSA 
   94.7% Attendance rate (Excluding attendance by proxy): Board of Directors fulfilled due diligence in supervision
   83 Patents: Number of valid patents 

   94 Trademarks: Number of valid trademarks  

   Human capital management（10 Performance Highlights） 

   91%: Average retention rate of PEC Taiwan

   69% : Nearly 70% of our employees hold Master’s and PhD degrees 
   49%: Nearly 50% of PEC Taiwan employees have been working with us for more than 5 years
   100%: Completion rate of employee performance assessment 
   100%: Employee reinstatement and retention rate after parental leave 
   100%: Implementation rate of maternal health protection program in Taiwan 
   Gender-balanced: Equivalent number of male and female employees in Taiwan
   58+ sessions 252 participants: Internal and external occupational safety and health staff training in Taiwan 
   NT$2.52 million: Total employee benefit expense in Taiwan 
   0 occupational accident  

   Product quality and patient safety（8 Performance Highlights） 

   4,000+: Comprehensive quality and safety management, standard operating procedures and various plans and reports
   54,168 hours of training  2,234 participants: Good Manufacturing Practice (GMP)  for Medicinal Products training 
   Top 3 sustainability management priorities for suppliers: Advocated to 177 suppliers 
   100% for 3 consecutive years: All the vendors that required to sign quality agreements, internal assessments and on-site audits were 

     completed
   Taichung Plant passed the U.S. FDA’s plant inspection
   Stable and safe transnational supply chain: Established a US market supply
   Pharmacovigilance: Set up real-time global reporting mechanism and adverse event reporting emails: Safety@pharmaessentia.com 
   Second BESREMi® Periodic Safety Update Report (PSUR): Regularly issues safety reports  

   Environmental impacts（9 Performance Highlights） 

   Zero penalty: No incidents of violation of environmental laws and regulations
   Zero leakage: Toxic substances are properly managed without accidental leakage 
   Zero emission: No Ozone Depleting Substances (ODS) were emitted during production process 
   Air pollutant emissions are lower than the legal value: Monitor air pollutant emission data actively
   Reduce CO2e intensity per unit output by 40.5%: Mitigate the impacts of GHGs on the globe 
   Reduce waste intensity per unit output by 21.3%: Improve productivity and reduce the impacts on the environment
   Greenhouse Gas Management: Completed ISO 14064-1:2018 Greenhouse Gas Inventories In 2019, and received third-party certifications 
   Introduction of the Management System: It is expected to implement IS14001:2015 Occupational Safety and Health Management 

     System by 2023 

   7.779 million liters of process water is recycled and reused: Effectively utilize water resources throughout the production process    

     Access to healthcare and medicine pricing（6 Performance Highlights）

   Ropeginterferon alfa-2b (P1101) is used by more than 1,500 PV patients: BESREMi® is now available in 30 countries worldwide. 

     Treating more  than 1,500 patients cumulatively as of December 31, 2021 

   Accumulated certification of orphan drugs for PV in 2 countries: Ropeginterferon alfa-2b (P1101) has received orphan drug approval 

    for the treatment of PV in the U.S. and South Korea 

   Reliable and stable drug supply chain: PEC has built a comprehensive global supply chain and did not receive any incident reports

     related to product quality in 2021 

   Strengthening the medical system and increasing shared value: Sponsored MPN Asia, an international seminar for MPN for 5 

     consecutive years

   Patient support actions: Established "MPNiCare" platform, commenced “SOURCE” program in the U.S., and formulated the first MPN 

      center in Taiwan 

   Engaging in global patient welfare promotional organizations: Supported activities by foundations and patient organizations

     including ASH Foundation, The Hematology Society of Taiwan, and MPN Research Foundation   

For the full report,  please go to http://www.pharmaessentia-esg.com    

 Disclaimer 

 The information provided herein is for reference only and is not to be relied upon as making a complete description of the Company’s operations. Shall the content involve any predictions, the Company does not imply, declare nor guarantee the correctness or reliability of the information provided. Users shall be solely responsible for their judgment and their undertaking of risks.